ADIL - CIK 0001513525
The table below shows ADIAL PHARMACEUTICALS, INC.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $2.62M | $3.23M | $1.27M | $1.95M | $8.40M | $5.85M |
| SG&A | $5.18M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $5.06M |
| $5.62M |
| $8.91M |
| $9.34M |
| $5.07M |
| Operating income | -$7.80M | -$8.28M | -$6.89M | -$10.86M | -$19.29M | -$10.93M |
| Income tax | - | - | - | -$502.00 | -$94.08K | - |
| Net income | -$7.98M | -$13.20M | -$5.12M | -$12.73M | -$19.42M | -$10.89M |
| EPS (diluted) | -$11.93 | -$68.01 | -$3.60 | -$12.71 | -$1.04 | - |